ImClone refiles on cancer drug
ImClone Systems has refiled an application with federal regulators to market Erbitux, the cancer drug at the centre of insider-trading scandal. The company, whose refiling was announced on Thursday,
ImClone Systems has refiled an application with federal regulators to market Erbitux, the cancer drug at the centre of insider-trading scandal. The company, whose refiling was announced on Thursday,